Janux Therapeutics JANX Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's cash ratio?
- Janux Therapeutics (JANX) reported cash ratio of 0.9× in Q1 2026.
- How has Janux Therapeutics's cash ratio changed year-over-year?
- Janux Therapeutics's cash ratio decreased by 79.1% year-over-year, from 4.2× to 0.9×.
- What is the long-term trend for Janux Therapeutics's cash ratio?
- Over 5 years (2020 to 2025), Janux Therapeutics's cash ratio has grown at a -3.1% compound annual growth rate (CAGR), from 2.5× to 2.1×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.